Integrated Filing- Financial

Piramal Pharma Limited has announced a board meeting to review the integrated financial results for the quarter and nine months ended December 31, 2024. Key highlights include total income of ₹1,273.02 Cr and profit after tax of ₹118.80 Cr for the three months, compared to ₹210.06 Cr in the previous quarter.

The year-to-date profit stands at ₹414.13 Cr, reflecting a solid recovery.

Despite a sequential decline in key metrics, the overall financial health indicates stability, suggesting a positive outlook for resilient investor sentiment amid ongoing operational adjustments.